

Interests Register

Atrial fibrillation (update) Advisory Committee

Publication Date: 17/09/2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Simon Mackenzie	Committee Chair	Direct, non-financial professional and personal	Honorary professor St George's University of London	2015	On application		Non-specific Declare and participate
Simon Mackenzie	Committee Chair	Direct, financial	Secondary care doctor Lewisham CCG	2017	On application		Non-specific Declare and participate
Neil Andrews	Committee Topic Adviser	Direct, financial	Private Practice that includes patients with atrial fibrillation. No new patients since 01/11/2017.	01/01/2012	On application	25/04/2018	No private patients seen since 25/04/2018 Declare and participate
Neil Andrews	Committee Topic Adviser	Direct, financial	One of 10 Directors of Portsmouth Cardiac Associates which performs non-invasive investigations for private patients including patients with atrial fibrillation. Echo machine – GE; Holter – Spacelabs; Loop recorder – Novacor.	2005	26/10/18	29/10/18	None of these devices are under consideration according to AF scope. Declare and participate.

Matthew Bates	Committee Member	Direct, financial	Low volume private practice for cardiology / electrophysiology (<£10,000 p.a. income). I have never performed any private practice procedures in patients with atrial fibrillation and would refrain from private practice involving patients with atrial fibrillation during any involvement with the NICE AF management guidelines update committee.	11/2015	On application		Declare and participate Has not seen and will not see private patients with atrial fibrillation for the duration of the guideline.
Matthew Bates	Committee Member	Direct, financial	Very low volume market research-type surveys on cardiac conditions (<£200 p.a. income). No direct payments from any commercial source involved in the management of cardiac conditions.	08/2002	On application		Non-specific. Declare and participate.
Matthew Bates	Committee Member	Direct, non-financial professional and personal	Attendance at RCP SAC Cardiology meetings as ARCP Chair for Northern Deanery (intermittent ongoing attendance on behalf of TPD).	2017	On application		Non-specific. Declare and participate

Matthew Bates	Committee Member	Direct, non-financial professional and personal	I have co-authored publications and provided editorial comment in the field of AF management and adherence to guidelines	2017	On application		Specific Declare and participate Asked to withdraw if publications included in the evidence review.
Matthew Bates	Committee Member	Direct, non-financial professional and personal	I am actively involved in several ongoing research trials in the area to determine the effectiveness of different management strategies (e.g. CRAFT study co-applicant and PI).	2017	On application		Non-specific Declare and participate
Antony Chuter	Committee Member	Direct, non-financial professional and personal	Chair of the Charity Pain UK (Non remunerated) 2013 - Present	2013	On application		Non-specific. Declare and participate
Antony Chuter	Committee Member	Direct, non-financial professional and personal	Chair of the Patient Liaison Committee at the British Pain Society (Non remunerated)	2012	On application	2017	Non-specific. Declare and participate
Antony Chuter	Committee Member	Direct, financial	Spoke about living with pain to Executives from Pfizer for 30 mins (honourarium in line with ABPI code)	11/2017	On application	11/2017	Non-specific. Declare and participate

Antony Chuter	Committee Member	Direct, financial	Judge for the Grunenthal Pain Awards (Honorarium in line with ABPI code)	2015	On application	2017	Non-specific. Declare and participate
Antony Chuter	Committee Member	Direct, non-financial professional and personal	As chair of the Patient Liaison committee at the British Pain Society, I was lead for 'Understanding and managing pain after surgery' an information booklet for patient. Produced by the British Pain Society's Patient Liaison Committee and the Acute Pain Special Interest Group. Launched May 2016 (Non remunerated)	May 2016	On application	May 2016	Non-specific Declare and participate
Antony Chuter	Committee Member	Direct, financial	Advised on the editing of lay summaries (re cancer treatments) for Envision	10/2017 and 10/2018	26/10/2018	10/2017 and 10/2018	Declare and participate Non-specific.
Antony Chuter	Committee Member	Direct, financial	Attended an advisory board for Pfizer regarding Chronic Pain on behalf of Pain UK (Pain UK receive payment for our time at this meeting, I only receive expenses)	10/2018	26/10/2018	10/2018	Declare and participate Non-specific.

Antony Chuter	Committee Member	Direct, financial	Attended an advisory board for Pfizer regarding Chronic Pain (honorary in line with ABPI code)	03/2018	26/10/2018	03/2018	Non-specific. Declare and participate
Antony Chuter	Committee Member	Direct, financial	Spoke about living with pain in a video for internal use only in Pfizer. (honorary in line with ABPI code)	12/2017	26/10/2018	12/2017	Non-specific. Declare and participate
Antony Chuter	Committee Member	Direct, financial	Q Research Advisory Board (Lay Member), 2 meetings per year	2015	26/10/2018		Non-specific. Declare and participate
Antony Chuter	Committee Member	Direct, financial	Attended an advisory board for Pfizer regarding Chronic Pain on behalf of Pain UK (Pain UK receive payment for our time at this meeting, I only receive expenses)	June 2019	10/09/2019	June 2019	Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, financial	Lancaster University NIHR funding for a fit for Joint replacement surgery programme	2019	10/09/2019		Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, financial	ONO 2 day workshop on painful rare conditions, one day focused on Acromegaly and one day focused on NETS (A rare	2019	10/09/2019	2019	Non-specific Declare and participate

			cancer)– acting as a patient rep.				
Anthony Chuter	Committee Member	Direct, financial	ONO commenting on internal patient involvement guide (included how to engage with patients and support them, ensuring their contracts for patients used lay language.	2019	10/09/2019	2019	Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, financial	ePAMS+ University of Edinburgh A NIHR Programme grant looking at Antimicrobial Stewardship using electronic prescribing systems in hospitals in England.	2019	10/09/2019		Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, financial	British Pain Society funded Clulow award Pain & HTLV1 Looking at how pain effects people living with HTLV1 and how better to treat the symptoms– Head of PPI	2018	10/09/2019		Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, financial	Advised the editing of lay summaries (all regarding cancer treatments) for Envision	Oct 2018	10/09/2019		Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, non-financial,	European Federation of Pain Conference Valencia	Sept 2019	10/09/2019	Sept 2019	Non-specific Declare and participate

		professional and personal	Attended and spoke as a panel member as chair of Pain UK at a session re coproduction with patients of research in pain - only paid reasonable expenses				
Anthony Chuter	Committee Member	Direct, financial	Consultancy work for Vivari Healthcare to make videos regarding the patient experience of living with Opioid induced constipation, and testosterone failure and then treatment with testosterone gel. For internal company use only.	Sept 2019	10/09/2019	Sept 2019	Non-specific Declare and participate
Anthony Chuter	Committee Member	Direct, non-financial	Attended a meeting in Brussels regarding Patient Lay summaries in research. The Synergist funded the travel, accommodation and subsistence (reasonable expenses)	Nov 2019	08/01/20		Non-specific Declare and participate
Nazish Khan	Committee Member	Direct, non-financial professional and personal	Update on anticoagulation – publication pending in the British Journal of Cardiac Nursing	07-08/2018	On application	07-08/2018	Specific.

							No opinion stated on what anticoagulants should be prescribed. Declare and participate
Nazish Khan	Committee Member	Direct, non-financial professional and personal	Gave a presentation on the safe prescribing of anticoagulants (based on ESC or ISTH guideline recommendations and the findings of the studies included) - delivered on October 13th in Birmingham. The educational event was hosted by MediConference and aimed at GPs.	13/10/18	26/10/18	13/10/18	Specific No opinion stated on what anticoagulants should be prescribed. Declare and participate
Gerry Lee	Committee Member	Direct, non-financial, professional and personal, non-specific	Member of Specialised Cardiac Improvement Programme: CRM Clinical Pathways Workgroup (examining pathways for ablation in AF patients)	02/02/2019	01/04/2019		Non-specific Declare and participate
Thomas McAnea	Committee Member	Direct, financial	I am a Partner in our practice and thus share in profits generated as a GP practice. I do not receive income from drug companies nor do I have any involvement in clinical	02/01/18	10/01/19		Non-specific Declare and participate

			trials. I work as a GP Trainer and Programme Director at Health Education England but none of these roles are relevant to the work of the committee.				
Thomas McAnea	Committee Member	Direct, financial	Clinical Director of a Primary Care Network. This is a paid role for providing leadership to our network of 6 practices as part of the new PCN scheme across England.	July 2019	15/10/19	June 2021	Non-specific Declare and participate
Irene McGill	Committee Member		None.		On application		
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal	I am the Director of the University of Birmingham's Institute of Cardiovascular Sciences	2011	On application		Non-specific Declare and participate
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal	Part of my academic role is fulfilled through honorary contracts with the two major NHS trusts in the region. I coordinate a large atrial fibrillation clinic at SWBH NHS Trust and coordinate the inherited cardiac	2011 (2015 for UHB)	On application		Specific Declare and participate

			conditions service at UHB NHS Trust.				
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal	I am the chairperson of AFNET, an academic research organisation based in Germany that coordinates research projects to improve outcomes in patients with atrial fibrillation.	2015	On application		Specific Declare and participate The chair role is coordination, oversight, and representation. The research is mainly focused on biomarkers for AF which is not covered by the guideline.
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal	I chair the education committee of the European Society of Cardiology overseeing the educational activities of the ESC such as the European Exam in General Cardiology, its online courses, webinars, etc.	2016	On application		Non-specific Declare and participate
Paulus Kirchhof	Committee Member	Indirect, financial	Funding for research projects from public funders (e.g. NIHR, German Ministry of Education and Research, British Heart Foundation, Medical Research Council) and from industry		On application		Declare and withdraw from recommendations for the following questions: - What are the most accurate methods for detecting constant or

			<p>partners for investigator-initiated controlled clinical trials. Funding is received by University of Birmingham and by AFNET. The majority of the currently active research projects are in the field of atrial fibrillation.</p> <p>List of relevant publications:</p> <p>-Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, WeimarC, Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72 hours Holter ECG in patients with ischemic stroke. Stroke 2013; 44: 3357-3364.</p> <p>-Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS.</p> <p>Management of atrial high-rate episodes detected by cardiac implanted electronic</p>				<p>intermittent pulse irregularities in people with symptoms suggestive of atrial fibrillation and in people with cardiovascular risk factors? (Grond 2013 and Freedman 2017)</p> <p>-What is the most clinically and cost-effective anticoagulant therapy for stroke prevention in people with atrial fibrillation? (Kirchhof P, Radaideh G, 2018; Romero J, Cerrud-Rodriguez 2018; Kirchhof P, Haeusler KG 2018; DeCaterinaR, Bruggenjurgun B 2018; De Caterina R, Bruggenjurgun B 2017; Hanon O Vidal JS, 2017 ; Di Biase L, Callans D 2017</p> <p>-What is the clinical and cost effectiveness of different ablative and</p>
--	--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

			<p>devices. Nat Rev Cardiol. 2017.</p> <p>-Kirchhof P, Radaideh G, Kim Y, Lanas F, Haas S, Amarenco S, Turpie A, Bach M, Lambelet M, Hess S, Camm A. Global Safety Analysis of Rivaroxaban: A Pooled Analysis of the Global Prospective, Observational XANTUS Program. J Am Coll Cardiol. 2018; published on line June 2018</p> <p>- Romero J, Cerrud-Rodriguez RC, Diaz JC, Michaud GF, Taveras J, Alviz I, Grupposo V, Cerna L, Avendano R, Kumar S, Kirchhof P, Natale A, Di Biase L.</p> <p>Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a</p>				<p>non-ablative therapies in people with atrial fibrillation? [only the part of the question on non-ablation requires withdrawal] (Kirchhof P for the XANTUS investigators; Kotecha D, 2017; Piccini JP, 2018; 2016-2019. The RATE-AF trial</p> <p>What is the clinical and cost effectiveness of discontinuing anticoagulation in people whose atrial fibrillation has resolved? (Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD, Sharma M, Wyse DG, Champagne J, Essebag V, Wells G, Gupta D, Heidbuchel H, Sanders P,</p> <p>Birnie DH. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation</p>
--	--	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

			<p>systematic review and meta-analysis of randomized controlled trials. Europace. 2018.</p> <p>- Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR,</p> <p>Massaro T, Mont L, Nielsen JC, Nolker G, Piccini JP, De Potter T, Scherr D,</p> <p>Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018; published on line 20 March.</p> <p>- De Caterina R, Bruggenjurgan B, Darius H, Kohler S, Lucerna M, Pecan L, Renda G, Schilling RJ, Schliephacke T,</p>				<p>(OCEAN) trial. Am Heart J. 2018;197:124-32).</p>
--	--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	-----------------------------------------------------

			<p>Zamorano JL, Le Heuzey JY, Kirchhof P.</p> <p>Quality of life and patient satisfaction in patients with atrial fibrillation on stable</p> <p>vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral</p> <p>anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.</p> <p>Arch Cardiovasc Dis. 2018;111(2):74-84.</p> <p>- De Caterina R, Bruggenjurgan B, Darius H, Kohler S, Lucerna M, Pecan L, Renda</p> <p>G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P.</p> <p>Quality of life and patient satisfaction in patients with atrial fibrillation on stable</p> <p>vitamin K antagonist treatment or switched to a</p>				
--	--	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--

			<p>non-vitamin K antagonist oral</p> <p>anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.</p> <p>Arch Cardiovasc Dis. 2017.</p> <p>- Hanon O, Vidal JS, Le Heuzey JY, Kirchhof P, De Caterina R, Schmitt J, Laeis</p> <p>P, Mannucci PM, Marcucci M. Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. Int J Cardiol.2017, published on line January 2017</p> <p>-Kirchhof P for the XANTUS investigators. Outcomes after catheter ablation and</p> <p>cardioversion in patients with non-valvular atrial fibrillation: results from the</p> <p>prospective, observational XANTUS study. Europace. 2017.</p>				
--	--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--

			<p>-Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, Mehta S, Slinn</p> <p>G, Stanbury M, Steeds RP, Townsend JN. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open. 2017;7:e015099.</p> <p>-Piccini JP, Kirchhof P. Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both? Eur Heart J 2018;39:450-2.</p> <p>-2016-2019. The RATE-AF trial (Career Development Fellowship). National Institute of Health Research (NIHR)</p>				
--	--	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--

			<p>2016 EAST – AFNET 4 trial, EAST is registered at ClinicalTrials.gov, ISRCTN, and EU Clinical Trials Register The EAST - partially funded by the German Centre for Cardiovascular Research (DZHK)</p> <p>-Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD, Sharma M,</p> <p>Wyse DG, Champagne J, Essebag V, Wells G, Gupta D, Heidbuchel H, Sanders P,</p> <p>Birnie DH. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-</p> <p>Catheter Ablation for Atrial Fibrillation (OCEAN) trial. Am Heart J.</p> <p>2018;197:124-32.</p> <p>-Di Biase L, Callans D, Georg Haeusler K,</p>				
--	--	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--

			<p>Hindricks G, Al-Khalidi H, Mont L,</p> <p>Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017;19:132-8. doi: 10.1093/europace/euw368</p>				
Paulus Kirchhof	Committee Member	Indirect financial	<p>My institution receives honoraria for my work for medical and device companies active in atrial fibrillation, e.g. as steering committee member in industry-sponsored clinical trials, or for invited lectures delivered during industry-organised symposia at major cardiology meetings.</p>	2016	On application		<p>Specific</p> <p>Declare and participate</p>

			Some of this work is related to atrial fibrillation.				
Paulus Kirchhof	Committee Member	Direct, financial	I receive payments for strategic advice, lectures, and grant reviews from academic institutions and from public funding bodies in the UK and in Europe. While some advice may be related to my knowledge in atrial fibrillation, it is more often based on my general standing in academia.	2010	On application		Non-specific Declare and participate Would be excluded if expressing an opinion of a topic included in the guideline
Paulus Kirchhof	Committee Member	Direct, financial	I am listed on two patents filed by University of Birmingham (Atrial Fibrillation Therapy, WO 2015140571; Markers for AF, WO 2016012783)	2015&2016	On application		Non-specific Declare and participate
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal, specific	I have coordinated (older) review articles related to AF detection depending on monitoring intensity: <i>Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/ EHRA consensus conference on atrial fibrillation entitled</i>	2009	01/04/2019	2009	Withdraw from the recommendations for the questions: What are the most accurate methods for detecting atrial fibrillation in people with cardiovascular risk factors and/or symptoms suggestive of AF

			<i>'research perspectives in atrial fibrillation'</i>				What is the most clinically and cost-effective method for detecting atrial fibrillation in people with cardiovascular risk factors and/or symptoms suggestive of AF?
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal, specific	I am the CI of one of the ongoing controlled trials comparing NOAC therapy to no anticoagulation in patients with pacemaker-detected "atrial high rate episodes": <i>Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial</i>	2017	01/04/2019		Withdraw from the recommendations for the question: What is the most clinically and cost-effective anticoagulant therapy for stroke prevention in people with atrial fibrillation?
Paulus Kirchhof	Committee Member	Direct, non-financial, professional and personal, specific	Investigator on <i>The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial</i>	2018	01/04/2019		Withdraw from the recommendations for the question: What is the clinical and cost-effectiveness of discontinuing anticoagulation in people

							whose atrial fibrillation has resolved?
Chakravarthi Rajkumar	Committee Member	Indirect, financial	Manufacturers of DOAC has funded the dept of Manchester via the University Medical School for educational meeting	11/2018	28/11/2018	11/2018	Specific Declare and participate
Yohan Samarasinghe	Committee Member	Direct, financial	Sponsored to attend Diabetes Meetings and Conferences by a number of Pharmaceutical Companies involved in Diabetes Care	2002	On application	ongoing	Non-specific. Declare and participate.
Yohan Samarasinghe	Committee Member	Direct, financial	I have given non-promotional educational talks to primary and secondary care, recompensed by Pharmaceutical companies who specialise in Diabetes Care.	2002	On application	ongoing	Non-specific. Declare and participate
Yohan Samarasinghe	Committee Member	Direct, non-financial professional and personal	Attended monthly departmental meetings sponsored by DOAC companies	2016	28/11/2018	ongoing	Specific Declare and participate
Jaspal Taggar	Committee Member	Direct, non-financial professional and personal	AF screen international collaboration (member)	2016	On application		Non-specific Declare and participate

Jaspal Taggar	Committee Member	Direct, financial	Staff member University of Nottingham No AF publications planned for the duration of the guideline.	2012	On application		Non-specific Declare and participate
Keith Tyndall	Committee Member	N/A	None.		On application		
Keith Gomez	Co-opted Committee Member	Direct, financial	Honoraria to speak at industry sponsored educational events and international conferences from Bayer, Pfizer, Novo Nordisk. This has been in the field of bleeding disorders only and not anticoagulation.	2010	On application	ongoing	Non-specific. Declare and participate
Keith Gomez	Co-opted Committee Member	Direct, non-financial professional and personal	Trustee of the British Society for Haemostasis and Thrombosis	2010	On application	ongoing	Non-specific Declare and participate
Narain Moorjani	Co-opted Committee Member	Direct, financial	Private practice - will be refraining from seeing private patients referred for isolated atrial fibrillation surgery for the duration of the guideline		On application		Specific Interest has ceased Declare and participate.

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.